植物来源生物碱治疗过敏性鼻炎：证据、暴露、安全性与转化就绪度

文献信息

中文摘要

背景： 过敏性鼻炎（AR）是一种由过敏原驱动、IgE介导的鼻黏膜炎症性疾病。现有疗法对许多患者有效，但症状控制不完全、依从性欠佳以及治疗偏好使人们对新的局部作用药物持续保持兴趣。植物来源生物碱常被提出作为抗过敏候选物；然而，文献常将天然化合物与半合成衍生物及合成类似物混为一谈，并对计算预测、细胞实验、动物模型和临床发现给予相似权重。方法：对已在AR中研究的化学定义明确的生物碱进行了结构化批判性综述。转化证据按Tier I（对照人体AR证据）至Tier IV（细胞、组学或计算证据）分级，同时单独评估机制置信度。结果：九种经典植物生物碱具有来自直接AR或过敏性鼻炎合并哮喘综合征模型且含鼻部结局的Tier II证据：小檗碱、紫堇灵、胡椒碱、青藤碱、去甲乌药碱、白鲜碱、玫瑰树碱、warifteine和methylwarifteine。报告的作用包括鼻部症状减少、肥大细胞活化降低、IgE和2型细胞因子反应降低以及嗜酸性炎症减轻。Warifteine和methylwarifteine构成内部一致性最强的临床前系列；大多数其他候选物依赖于单一短疗程、基于卵清蛋白的研究。随机化、盲法结局评估、临床相关对照、鼻部药代动力学和直接靶点结合实验并不常见。安全性具有化合物特异性，并实质性改变转化排序。相关关注包括药物-药物相互作用、非IgE介导的肥大细胞活化、全身性肾上腺素能效应、反应性代谢物和遗传毒性。鼻内异丙托溴铵为水样鼻漏提供了对照人体证据，但它是专门设计的合成阿托品衍生物，不能验证植物生物碱作为一个治疗类别。结论：因此，现有证据支持将选定生物碱用作先导骨架和机制探针，而非已确立的AR治疗。进展需要经过认证的化学、兼顾母体与代谢物的鼻部暴露、人体鼻部系统中的因果研究、活性对照疗效以及适合长期治疗通常非危及生命疾病的安全边际。

英文摘要

Allergic Rhinitis (AR) is an allergen-driven, IgE-mediated inflammatory disease of the nasal mucosa. Established therapies are effective for many patients, but incomplete symptom control, suboptimal adherence, and treatment preference sustain interest in new locally acting agents. Plant-derived alkaloids are frequently proposed as anti-allergic candidates; however, the literature often conflates natural compounds with semisynthetic derivatives and synthetic analogues and gives similar weight to computational predictions, cell assays, animal models, and clinical findings. A structured critical review of chemically defined alkaloids investigated in AR was conducted. Translational evidence was graded from Tier I (controlled human AR evidence) to Tier IV (cellular, omics or computational evidence), while mechanistic confidence was assessed separately. Nine canonical plant alkaloids had Tier II evidence from direct AR or combined allergic rhinitis and asthma syndrome models with nasal outcomes: berberine, corynoline, piperine, sinomenine, higenamine, dictamnine, ellipticine, warifteine and methylwarifteine. Reported effects included fewer nasal symptoms, reduced mast-cell activation, lower IgE and type 2 cytokine responses, and less eosinophilic inflammation. Warifteine and methylwarifteine constitute the most internally coherent preclinical series; most other candidates depend on a single short-duration, ovalbuminbased study. Randomisation, blinded outcome assessment, clinically relevant comparators, nasal pharmacokinetics and direct target-engagement experiments were uncommon. Safety is compound-specific and materially changes translational rank. Relevant concerns include drug-drug interactions, non-IgE-mediated mast cell activation, systemic adrenergic effects, reactive metabolites, and genotoxicity. Intranasal ipratropium provides controlled human evidence for watery rhinorrhoea, but it is a purpose-designed synthetic atropine derivative and cannot validate plant alkaloids as a therapeutic class. The available evidence therefore supports the use of selected alkaloids as lead scaffolds and mechanistic probes, but not as established AR treatments. Progress requires authenticated chemistry, parent- and metabolite-aware nasal exposure, causal studies in human nasal systems, active-comparator efficacy and safety margins appropriate for long-term treatment of a usually non-life-threatening disease.